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Abstract
Introduction Needle-related procedures are considered
as the most important source of pain and distress in
children in hospital settings. Considering the physiological
and psychological consequences that could result from
these procedures, management of pain and distress
through pharmacological and non-pharmacological
methods is essential. Therefore, it is important to have
interventions that are rapid, easy-to-use and likely to
be translated into clinical practice for routine use. The
aim of this study will be to determine whether a device
combining cold and vibration (Buzzy) is non-inferior to a
topical anaesthetic (liposomal lidocaine 4% cream) for
pain management of children undergoing needle-related
procedures in the emergency department.
Methods and analysis This study will be a randomised
controlled non-inferiority trial comparing the Buzzy device
to liposomal lidocaine 4% cream for needle-related pain
management. A total of 346 participants will be randomly
assigned in a 1:1 ratio to one of the two study groups. The
primary outcome will be the mean difference in pain intensity
between groups during needle-related procedures. A noninferiority margin of 0.70 on the Color Analogue Scale will
be considered. A Non-inferiority margin of 0.70 on the Color
Analogue Scale will be considered. The secondary outcomes
will be the level of distress during the procedure, the success
of the procedure at first attempt, the occurrence of adverse
events, the satisfaction of both interventions and the memory
of pain 24 hours after the procedure. The primary outcome will
be assessed for non-inferiority and the secondary outcomes
for superiority.
Ethics and dissemination This study protocol was reviewed
and approved by the institutional review board of the study
setting. Findings of this trial will be disseminated via peerreviewed publications and conference presentations.
Trial registration number NCT02616419.

Introduction
Background and rationale
Needle-related procedures, such as venipunctures and intravenous catheter insertions,
are considered as the most important source

Strengths and limitations of this study
►► This is the first study to assess the efficacy of the

Buzzy device in Canada.
►► The large sample size of 346 participants will pro-

vide enough power to demonstrate the non-inferiority of the Buzzy device compared with a topical
anaesthetic.
►► The non-inferiority margin is justified on both clinical
and statistical grounds.
►► This study presents potential clinical implications
for nursing and medical practices in the emergency
department.
►► The main limitation of this trial is the impossibility
to blind participants and personnel to intervention
allocation.

of pain and distress in children in hospital
settings.1–4 The intensity of pain and distress
caused by these procedures can vary from
mild to moderate for some, while for others,
it may be severe.4–7 It is now recognised that
even a such minor procedure, can result in
numerous physiological, psychological and
emotional consequences.8 9 Among these,
needle phobia is the most important and prevalent one with more than 60% of children
reporting an extreme fear of needles following
a bad needle experience.10 These children
are more likely to report higher levels of pain
and distress from subsequent procedures,11 12
and they can experience physiological symptoms, such as vasovagal reactions and an
increased heart rate and blood pressure.13 14
Furthermore, they can also develop healthcare avoidance behaviours in adulthood, such
as delays in care, non-compliance of immunisation requirements and avoidance of treatment.10 14 Consequently, nurses play a critical
role in the assessment and management of
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emergency paediatrician and pain researcher in the USA,
developed a pain blocker device called Buzzy (MMJ Labs,
Atlanta, Georgia, USA) specifically for pain management
of children undergoing needle-related procedures. The
Buzzy is a bee-shaped device combining vibration (body
of the bee) and cold (removable ice wings).39 The theoretical bases explaining the action of the device are the
Gate Control Theory40 and the diffuse noxious inhibitory control theory, which both involve modulation of
the transmission of pain.39 Therefore, it is theorised that
the simultaneous use of vibration and cold would provide
optimal pain management.
To date, there have been some randomised controlled
trials that have investigated the efficacy of the Buzzy
device on pain management in children undergoing needle-related procedures in various medical
settings.41–49 However, these studies present several
limitations such as the absence of an active comparator,41 43 44 46–48 the lack of prior power analyses or sample
size calculation,43 44 lack or unclear allocation concealment,41–44 47 48 among others. Of those studies, only two
have been conducted in the ED setting,45 49 and none
have been done in Canada. The Buzzy device seems to be
a promising method to reduce and control procedural
pain in the ED, and it would be interesting to determine if the it is at least as efficacious as a topical anaesthetic for pain management in children and adolescents
during needle-related procedures.
Study objectives
Primary objective
To determine if a device combining cold and vibration
(Buzzy) is non-inferior (no worse) to a topical anaesthetic
(liposomal lidocaine 4% cream) for pain management in
children undergoing needle-related procedures in the
ED.
Secondary objectives
To determine if, in comparison with a topical anaesthetic
(liposomal lidocaine 4% cream), the Buzzy device will:
►► Decrease the level of distress during the needle-related procedure.
►► Improve the success of the needle-related procedure
at first attempt.
►► Decrease memory of pain 24 hours after the needle-related procedure.
Other secondary objectives
To determine the occurrence of adverse events in
each study group.
►► To evaluate the satisfaction of parents, children and
nurses regarding the use of the Buzzy device and the
topical anaesthetic (liposomal lidocaine 4% cream).
►►

Method
This study protocol was developed in accordance with the
Standard Protocol Items: Recommendations for Interventional Trials recommendations.50
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children’s pain and distress, and the use of pharmacological and non-pharmacological interventions must be an
integrant part of nursing practice.15
Procedural pain management represents a major challenge for nurses, specifically for those working in the
emergency department (ED). Consequently, children
are at high risk for undertreatment of their pain during
needle-related procedures.16 Although healthcare professionals recognise the importance of providing adequate
procedural pain management, it is still suboptimal.8 17–19
Several studies have identified different barriers to using
available pharmacological and non-pharmacological
interventions for pain management in the ED.8 17–19
Barriers most frequently identified by nurses are time
constraints, heavy workload, staffing limitations, space
limitations, lack of knowledge and interruptions in the
continuity of care.15 20–22
Currently, the gold standard intervention for needle-related procedural pain is the application of a topical anaesthetic prior to the procedure and several systematic reviews
and meta-analysis have demonstrated its efficacy.23–26
However, topical anaesthetics require an application time
ranging from 30 min to 60 min, making their implementation for routine use difficult in the rapid and busy setting
of the ED.27 28 Indeed, a study led by Papa and Zempsky27
showed that only 28% of ED nurses used a topical anaesthetic during painful procedures they reported that main
barriers to using it were the onset of action of the drug,
treatment delays caused by application time and the
vasoconstriction of blood vessels.27 Consequently, topical
anaesthetics do not seem to be an optimal intervention
for procedural pain management in an acute care setting
where time constraints represent an important challenge
to adequate pain control.21 29 In addition, they had a
minimal side effect profile, including minor local reactions, such as mild irritation, redness, itching, oedema or
rash of the skin site following the application in 25%–50%
of cases.24 25 29–31
Other pharmacological and non-pharmacological
interventions have also been evaluated for their efficacy
on children’s pain management and distress during
needle-related procedures. Among these, there are sweettasting solutions,32 33 needle-free injection systems,34 35
vapocoolant sprays36 and distraction.37 38 However, even
if the efficacy of most of these interventions is well
demonstrated, their use remains limited in clinical practice.15 20–22 In fact, these interventions may require
specific training for healthcare professionals, preparation
time, or excessive cost, which represent barriers to their
implementation in the fast-paced environment of the ED
setting.15 20–22
The limited applicability of both pharmacological and
non-pharmacological interventions to manage procedural pain and distress in the ED setting demonstrates
a need for innovation in this domain. The optimal intervention for needle-related procedural pain management
in the ED would need to be rapid, easy-to-use and without
side effects. To answer this problem, Dr Amy Baxter, an
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Participants
Participants will be deemed eligible if they meet all of the
following inclusion criteria: (A) aged between 4 years old
and 17 years old, (B) presenting to the ED and requiring
a needle-related procedure (venipuncture or intravenous
catheter insertion), (C) having the ability to communicate in either French or English and (D) accompanied by
at least one parent/legal guardian who can understand,
read and speak French or English. We will exclude children with (A) a neurocognitive disability that precludes
them from assenting and participating to the study, (B)
an inability to self-report pain, (C) a critical or unstable
health status (<3 on the Canadian Triage and Acuity
Scale), (D) a Reynaud’s syndrome or sickle cell disease
with extreme sensitivity to cold; (E) a break or abrasion
on the skin where the device would be installed and (F) a
nerve damage or limited sensation in the extremity where
the needle-related procedure will be performed. We will
not exclude children who received analgesics, including
acetaminophen or ibuprofen, within the 4 hours prior to
presentation to the ED, but it will be documented.
Interventions
Experimental group: Buzzy device
Participants in the experimental group will receive the
Buzzy device intervention. The Buzzy is a palm-sized
device with two components: (1) body of the bee (vibration) and (2) removable and reusable ice wings (ice).
The body of the bee is a vibrating motor powered by two
alkaline AAA batteries, and it lasts for about 20 hours. The
vibration component is activated by a manual switch on
the top part of the device. The removable set of wings
contain a total of 18 g of ice. Each set of ice wings can stay
frozen for about 10 min at room temperature, and they
are reusable up to 100 times. Dimensions of the device
Ballard A, et al. BMJ Open 2019;9:e023214. doi:10.1136/bmjopen-2018-023214

are 8 cm × 5 cm × 2.5 cm. Enrolled children will have the
opportunity to hold and get familiarised with the Buzzy
device before the needle-related procedure.
Use and placement of the Buzzy device for the needle-related
procedure
The research nurse will follow the following steps, as
recommended by the manufacturer’s (MMJ Labs, Atlanta,
Georgia, USA): (1) immediately before the needle-related procedure, a set of ice wings will be retrieved
directly from the freezer of the ED unit. For optimal efficacy, the wings must be frozen solid; (2) the ice wings will
be inserted through the elastic bands fixed on the back of
the Buzzy device; (3) when the staff nurse will be ready to
clean the site and perform the needle-related procedure,
the research nurse will install the Buzzy device on the
child’s arm, above and as close as possible to the insertion
site (about 3–5 cm) with a reusable tourniquet, and the
vibration will be then activated. The Buzzy device will be
installed for about 30 to 60 s prior to the needle-related
procedure; (4) the device will have to be maintained on
the child’s arm throughout the procedure, at least until
the needle is removed; (5) when the procedure is over,
the two components of the device will be cleaned with
a disinfectant cleaner based on proprietary accelerated
hydrogen peroxide (Virox) as per the Infection Prevention and Control guidelines at the study setting; and (6)
the ice wings will then be put back in the freezer of the
unit for a subsequent procedure.
Physiological basis of the Buzzy device
The Gate Control Theory40 and the Descending Noxious
Inhibitory Controls (DNIC) are the theoretical bases
of the Buzzy device. More specifically, the Gate Control
Theory stipulates that the vibration component of the
device blocks the A-delta and C nociceptive fibres by
stimulating the A-beta non-nociceptive fibres. It activates
an inhibitory interneuron and results in a reduction of
the pain signal transmitted to the spinal cord.49 53 The
cold component (prolonged cold application 30–60 s)
stimulates the C nociceptive fibres and further blocks
the A-delta nociceptive pain transmission signal when
applied close to the needle insertion site.49 The second
theory behind the Buzzy device is the DNIC. More specifically, intense cold application stimulates the nociceptive
C fibres and activates a supraspinal modulation which,
in turn, increases the body’s overall pain threshold and
therefore produces a generalised hypoalgesia at the insertion site.39 54
Control group: topical anaesthetic (liposomal lidocaine 4% cream).
Participants in the control group will receive an application of liposomal lidocaine 4% cream (Maxilene, RGR
Pharma, LaSalle, Ontario, Canada) over the insertion
site 30 min before the needle-related procedure. The
topical anaesthetic cream will be applied by the research
nurse according to the manufacturer’s recommendations, and the site will be covered by a Tegaderm dressing
3

BMJ Open: first published as 10.1136/bmjopen-2018-023214 on 15 January 2019. Downloaded from http://bmjopen.bmj.com/ on December 10, 2019 at Univ Of West Ontario
GSTR101749364 Serials Acquisitions Unit. Protected by copyright.

Trial design and study setting
The study design will be a randomised, controlled,
non-inferiority trial with two parallel groups and a 1:1
allocation ratio. This study design is of interest when a
new intervention seems to present some advantages
over the reference intervention.51 Considering that the
Buzzy device seems to be less expensive, faster and easier
to use than the topical anaesthetic, which is the current
reference intervention, the choice of a non-inferiority
trial design was justified. As recommended for a non-inferiority trial,51 a study demonstrating the superiority of
the reference intervention compared with a placebo in
a similar context should be used as rationale to support
this study design.51 For this purpose, the study by Taddio
et al,52 which aimed to determine the efficacy of the liposomal lidocaine 4% cream over a placebo for managing
pain resulting from venipuncture in children in the ED,
was used as a reference trial to the current study.
This single-centre study will take place in the ED of
the CHU Sainte-Justine (Montreal, Quebec, Canada), a
university paediatric tertiary hospital centre with a census
of more than 80 000 ED visits per year.
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Mechanism of action
The mechanism of action of topical anaesthetics relies
on the reversible interruption of nerve conduction near
the application site by inhibiting sodium influx through
the voltage-gated sodium channels.30 59–61 This inhibition of sodium influx decreases the ability to generate
action potentials decreasing or blocking hereby pain
signals conduction. Following the application, a temporary loss of sensation in the limited area of application is
produced.60 61
Study proceedings
Recruitment
Eligible participants will be recruited consecutively in the
ED by two research nurses during study enrolment hours
(approximately 25 hours/weeks, depending on research
nurses’ availability). Potentially eligible children will be
initially assessed on arrival to the ED by triage nurses, staff
nurses and physicians. Then, when the treating physician
will have determined that a child will require a venipuncture or a catheter intravenous insertion, the research
nurse will approach the child and its family to confirm
study eligibility per the inclusion and exclusion criteria,
to explain the study in greater details and to answer all
questions before seeking consent for study participation.
Informed written consent will be obtained from parents
or legal guardians and assent will be obtained from children over 7 years old. Research nurses will maintain and
complete a screening and enrolment log to provide a
comprehensive list of all children who were screened for
eligibility. Recruited children will be randomly allocated
to either the experimental (Buzzy device intervention) or
the control group (liposomal lidocaine 4% cream).
4

Data collection and outcomes measures
Data collection will start following consent and enrolment. All data will be collected by one of the two research
nurses using a paper case report form (CRF) developed
and designed for this study. In addition to the primary
and secondary outcomes, sociodemographic and clinical data and covariates will be recorded. Data will be
collected at different end points: before randomisation
(T-0), 5 min before the needle-related procedure (T-1),
during the needle-related procedure (T-2), immediately
after the needle-related procedure (T-3) and 24 hours
after the needle-related procedure (T-4). Of note, the
needle-related procedure will be performed by the staff
nurse and not the research nurse.
Sociodemographic and clinical data
Before randomisation of participants (T-0), sociodemographic and clinical data will be collected by the research
nurse. These data will include age, sex, reason for consultation, previous experience(s) of needle-related procedures and analgesia received in the last 4 hours prior the
procedure. Contact preference and information will also
be obtained for a follow-up 24 hours after the needle-related procedure.
Primary outcome measure
The primary outcome will be the mean difference
in pain scores during the needle-related procedure
between groups. It will be assessed immediately after the
first needle-related procedure attempt using the Color
Analogue Scale (CAS) (T-3). This chosen end point aligns
with the recommendations on standard assessment of
post-needle pain.38 The CAS is a self-report paediatric pain
scale consisting of a plastic ruler with a mechanical slider
and showing a wedge-shape figure gradually changing in
colour from white to red. The white end means ‘no pain’
and the red end means the ‘worst pain’. The reverse side
of the scale is numbered from 0 cm to 10 cm with 0.25
increments, allowing investigators to quantify children’s
pain.62–64 The CAS has shown excellent psychometric
properties in children with acute pain in the ED.63 65 The
child will be shown the side with the wedge-shape figure
with the mechanical slider in the middle position and will
be asked to move the slider to the place that corresponds
to the pain he or she experienced during the needle-relate procedure. The meaning of each anchor will also
be explained to the child prior to using the scale. The
research nurse will record the corresponding pain score.
Secondary outcomes measures
The secondary outcomes will be the pain intensity during
the needle-related procedure (T-3), the level of distress
during the needle-related procedure (T-2, T-3), the
success of the procedure at first attempt (T-3), the satisfaction with both interventions (T-3), the occurrence of
adverse events and the memory of pain 24 hours after the
needle-related procedure (T-4).
Ballard A, et al. BMJ Open 2019;9:e023214. doi:10.1136/bmjopen-2018-023214
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(3M Canada Company, London, Ontario, Canada). The
topical anaesthetic cream and the Tegaderm dressing
will be removed just before the procedure. This intervention was chosen as an active control intervention as it
has been shown to be the most effective for pain management regarding needle-related procedures,23–26 and it is
also the standard care currently established in the study
setting.
The liposomal lidocaine 4% cream has been chosen
over other topical anaesthetics because of its shorter
application time (30 min) and its minimal vasoactive
properties that minimise potential interference with the
success of the needle-related procedure.52 Currently, the
gold standard topical anaesthetic cream is a combination
of lidocaine 2.5% and prilocaine 2.5% cream (Eutectic
Mixture of Local Anesthetics (EMLA)), but it requires an
application time of 60 min and it is frequently associated
with vasoconstriction of blood vessels.55–57 The liposomal
lidocaine 4% cream has also been chosen due to the
lower occurrence of rash reactions after its application,
which is often observed with the amethocaine 4% gel.58
The ametocaine 4% gel has also been associated with
vasodilatation and a risk of hypersensitivity with repeated
use.26
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Level of distress
Mean differences between groups on distress scores
during the needle-related procedure will be assessed
using the Procedure Behavior Check List (PBCL)69 (T-2)
and the Children’s Fear Scale (CFS)70 (T-3). The PBCL is
an observational scale specifically developed to evaluate
pain-related fear and anxiety during painful procedures.
This scale consists of a checklist with eight behavioural
items: muscle tension, screaming, crying, restraint used,
pain verbalised, anxiety verbalised, verbal stalling and
physical resistance. The observer has to rate the intensity of each behaviour on a scale from 1 to 5 (1=very mild
distress; 5=extremely intense distress).69 The research
nurse will record the PBCL during the first needle-related
procedure attempt (T-2). The CFS is a self-report scale
developed to measure fear of children during painful
experiences. This scale has five faces with a range of scores
from 0 to 4 as each face shows an increasing amount of
being scared moving from left to right.70 Immediately
after the first needle-related procedure attempt (T-3), the
child will be asked to choose the face that best shows how
much he was scared during the procedure. The child will
be informed that the first face is ‘not scared at all’ and the
last face is ‘the most scare possible’.70
Success of the procedure at first attempt
The proportion of participants achieving a successful
procedure at first attempt will be recorded as a binary
outcome (yes/no) (T-3). If the procedure is not successful
at first attempt, the research nurse will document the
number of attempts in the CRF.
Satisfaction
Satisfaction of both interventions will be evaluated using
three questionnaires tailored for children, parents and
nurses and including Likert scale questions and dichotomised (yes/no) questions. It will be assessed immediately after the needle-related procedure with parents and
Ballard A, et al. BMJ Open 2019;9:e023214. doi:10.1136/bmjopen-2018-023214

children (T-3) and when reaching 50% of the targeted
recruitment for nurses.
Adverse events
The proportion of participants experiencing an adverse
event will be recorded as a binary outcome (yes/no). An
adverse event will be defined as an unexpected medical
occurrence in a participant that may or may not be necessarily causally related to one of the two interventions.
Adverse events will be recorded after enrolment of the
participant until hospital discharge.
Memory of pain
The memory of pain will be assessed by comparing pain
scores between groups 24 hours after the needle-related
procedure using the FPS-R phrased in terms of recall66
(T-4). After the needle-related procedure, the research
nurse will give a paper copy of the FPS-R to each parent or
legal guardian with the corresponding instructions. They
will be informed that they will be contacted in the next
24 hours (±6 hours) by telephone, text message or email,
depending on their preference. The research nurse will
then ask the child to point at the face that corresponds
with how much pain they remember feeling during the
needle-related procedure at the ED. The child/parent
will report by telephone, text message or email the chosen
face (first, second, third, fourth, fifth and sixth) and the
research nurse will record the answer.
Covariates
Data will be collected from participants and their parents
for potential covariates. More specifically, preprocedural
pain (CAS) and preprocedural level of distress (PBCL and
CFS) will be assessed 5 min before the needle-related
procedure (T-1). Clinical data will be also recorded during
the needle-related procedure (T-2), including: type of
procedure (venipuncture and intravenous catheter insertion), healthcare professional performing the procedure
(nurse, nursing assistant and phlebotomist), presence of
parent/legal guardian during the procedure (one parent,
two parents and none), position of the child during the
procedure (sitting position, on a parent’s lap, dorsal decubitus and dorsal decubitus against his will), restraints used
during the procedure (yes/no) and use of other non-pharmacological interventions during the procedure.
Data management
All data collected with the CRFs will be manually entered
into an electronic database statistical software, and the
original CRFs will be kept on file at the participating
site. Data entry and coding will be performed by the
same person. A verification will be done by a second
person to compare with the original CRFs. Each participant’s file will be assigned an identification number to
preserve participant confidentiality. Files will be stored in
numerical order in a locked file cabinet in the principal
investigator’s office at the research centre. Files will be
maintained in storage for a period of minimum 25 years
5
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Pain intensity
Mean difference in procedural pain scores between groups
will also be assessed using the Faces Pain Scales – Revised
(FPS-R)66 immediately after the first needle-related procedure attempt (T-3). This self-report pain scale is the revised
version of the original scale previously developed by Bieri
et al.67 The FPS-R consists of six faces, and each of them
represents a greater intensity of pain than the previous one.
The face on the far-left shows ‘no pain’, and the face on the
far-right shows ‘very much pain’. On the reversed side of
the scale, each face is associated with a score ranging from
0 to 10 (0, 2, 4, 6, 8 and 10).66 This scale is the most recommended to evaluate procedural pain intensity in children,
particularly in children aged from 4 years old to 12 years
old.68 Immediately after the procedure, the research nurse
will ask the child to point the face that shows how much
pain he or she felt during the needle-related procedure.
The research nurse will document the pain score associated
with the face identified by the child.

Open access

Randomisation and allocation
An independent biostatistician of the Applied Clinical
Research Unit (Unité de Recherche Clinique Appliquée
(URCA)) will generate the sequence of randomisation
as per a computer-generated random listing of interventions applying a permuted block design with random
blocks stratified by age (4–7 years; 8–12 years; 13–17
years). The SAS software V.9.3 will be used to generate
the randomisation list using a prespecified seed to ensure
reproducibility and proof of random allocation. To
ensure concealment, the block size will not be disclosed.
The randomisation sequence will be stored at the URCA
for the whole duration of the study in order to keep the
investigators blinded from the study conditions. Enrolled
participants will be randomly assigned, in a 1:1 allocation
ratio, to receive either the experimental intervention
(Buzzy device intervention) or the control intervention
(liposomal lidocaine 4% cream).
The allocation concealment will be ensured by the
use of sequentially numbered, opaque and sealed envelopes previously prepared by the URCA. After the
enrolled participant will have completed all baseline
measurements, the appropriate numbered envelope will
be opened by the research nurse. Each envelope will
contain the randomisation number and the allocated
intervention.
Due to the major differences between the two interventions in appearance and timing of application, it will
not be possible to blind participants, parents, healthcare
providers and outcome assessors (research nurses) to the
participant’s allocation.
Data analyses
Sample size
The primary aim of this trial is to demonstrate the non-inferiority of the Buzzy device compared with a topical anaesthetic (liposomal lidocaine 4% cream) for procedural
pain management during needle-related procedures in
the ED. To determine the non-inferiority margin, an electronic survey was sent to 34 paediatric emergency physicians working in ED settings from Quebec and Ontario.
The following scenario and question were presented:
‘You are seeing a four year old female requiring an intravenous catheter for drug delivery. You are considering
two interventions for pain management during the
needle-related procedure: a topical anesthetic application (liposomal lidocaine 4% cream) or the Buzzy device.
You need to assume that both of these interventions have
the potential for reducing needle-related pain’. ‘What
is the greatest difference in mean pain reduction, on a
numerical scale from 0 to 10, between the topical anasthetic (liposomal lidocaine 4% cream) and the Buzzy
device you are willing to accept to routinely adopt the use
of the Buzzy device over the topical anesthetic (liposomal
lidocaine 4% cream) for needle-related procedures?’.
6

Respondents had to choose a difference ranging from
0.1 to 1.5 with 0.1 increments. The mean answer was
0.70; consequently, this value was chosen as the non-inferiority margin. Considering that the minimal clinically
significant difference on the CAS in children with acute
pain is 1.0 on a scale from 0 to 1071, the choice of a 0.70
non-inferiority margin is considered conservative and
insures that a minimally important difference would not
be missed. Therefore, a sample size of 346 participants
would be necessary to provide the trial with 90% power
to show the non-inferiority of the Buzzy device compared
with a topical anaesthetic at a one-sided alpha level of
0.025 with the use of a non-inferiority margin of 0.70 for
the per-procedural pain intensity. We anticipate no loss to
follow-up considering the short time frame between the
intervention and the assessment of the primary outcome.
The sample size was calculated using the G*Power software V.3.0.10.
Statistical methods
The primary analysis was designed to test whether the
Buzzy device is non-inferior to a topical anesthetic (4%
liposomal lidocaine) for procedural pain management
during needle-related procedures, as evaluated by calculating the CI for the mean differences in pain score
between groups. Non-inferiority would be declared if the
upper limit of the two-sided 95% CI (1-2α×100%CI), or
equivalently, the upper limit of the one-sided 97.5% CI,
for the between-group difference (experimental group –
control group) is less than the predetermined non-inferiority margin of ∆ 0.70. In this case, the null hypothesis
of inferiority will be rejected in favour of the alternative
hypothesis of non-inferiority, and the non-inferiority of
the Buzzy device over the topical anesthetic (liposomal
lidocaine 4% cream) will be established. A two-sided
95% CI will be applied, because it will provide additional
information if the superiority of the experimental intervention is demonstrated.51 In the case where the non-inferiority is met, superiority testing will be performed using
a two-sided alpha of 0.05 and in looking if the upper limit
of the CI is less than zero. Non-inferiority analysis will be
evaluated according to the intention-to-treat principle
(primary analysis) as well as to the per-protocol principle
(secondary analysis) to examine for consistency and avoid
bias.51
The secondary analysis was designed to test the superiority of the Buzzy device over the liposomal lidocaine
4% cream for secondary outcomes. The Student’s t-test
will be performed to compare the between-group mean
differences in preprocedural and procedural distress
scores. The memory of pain 24 hours after the needle-related procedure will also be evaluated by the Student’s
t-test to compare the mean differences in pain scores
between the experimental and control groups. The
proportion of participants achieving the success of the
procedure at first attempt will be calculated in each
group and compared using the χ2 test. Descriptive statistics will be used to report data collected on satisfaction,
Ballard A, et al. BMJ Open 2019;9:e023214. doi:10.1136/bmjopen-2018-023214
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after completion of the study, according to Health Canada
regulations for Health Canada Regulated Clinical Trials.

Open access

Patient and public involvement
Patients and public were not involved in the design,
recruitment and conduct of this study.

Discussion
This study protocol provides the rationale and methods
associated with a randomised controlled non-inferiority
trial comparing the Buzzy device to a topical anaesthetic
with the aim of improving procedural pain and distress
management in children undergoing needle-related
procedures. To our knowledge, it will be the first study
assessing the efficacy of the Buzzy device in Canada in
any clinical setting. A systematic review currently in
preparation by our team has identified several limitations in the studies previously conducted on the Buzzy
device (PROSPERO ID: CRD42017076531). The present
study is carefully designed to overcome these limitations
and provide rigorous evidence on its efficacy. The large
sample size will allow to determine if the Buzzy device is at
least as efficacious as the liposomal lidocaine 4% cream in
decreasing procedural pain. Therefore, this study has the
potential to improve clinical care and outcomes of children undergoing needle-related procedures in the ED.
Ballard A, et al. BMJ Open 2019;9:e023214. doi:10.1136/bmjopen-2018-023214

More specifically, findings from this trial could potentially
prevent pain and distress experienced by children, as well
as improve nurses’ pain management practices. In addition, this study could determine the efficacy of the Buzzy
device intervention across age ranges and developmental
differences. If the non-inferiority of the Buzzy is demonstrated, steps will be taken to eventually obtain a Medical
Device Licence from Health Canada to make this device
available in the EDs across Canada.
This study presents some limitations that are important
to recognise. First, considering the nature and the major
differences between both interventions, blinding of
participants and personnel will not be possible. Consequently, they will be aware of the intervention allocation
once the randomised envelop will be opened. This lack of
blinding could influence their behaviour and responses
to outcomes, particularly subjective ones like pain and
distress creating therefore a potential performance bias.74
However, the use of an active comparator (anaesthetic)
will potentially reduce or overcome this bias. Indeed,
a recent study75 has demonstrated that randomised
controlled trials using an active comparator reported
similar expectation ratings from participants between
groups. Second, it will not be possible to blind the
secondary outcome assessors (research nurses) as it will
require observing the participant’s behaviour during the
procedure. However, the primary outcome assessment
will be assessed by self-report, which is considered as a
primary source of evidence for paediatric pain intensity.76
This could increase the magnitude of the detection bias
as pain is a subjective measure.77 However, some have
argued that self-report assessment could be considered as
equivalent to blinding of outcome assessors considering
that it is not associated with an overestimated intervention effects, as is the case in psychotherapy meta-analyses.78 79 Third, we decided to exclude children under the
age of 4 years old as the large majority of blood samples of
this population are performed via micromethod (blood
collected in capillary tubes from finger sticks), and the
use of the Buzzy device is not applicable for these cases.
The inability of these children to self-report pain was also
a reason for exclusion.
Finally, although there is an increase in use and development of pharmacological and non-pharmacological
interventions, pain management remains suboptimal. It
suggests that evidence is not being translated in clinical
practice or that interventions are underused by healthcare providers.38 80 Therefore, it is important to provide
healthcare professionals with interventions that are likely
to be implemented into clinical practice for routine use.
The Buzzy device is an easy-to-use and fast intervention
that seems to be a promising option in the ED setting.
Ethics and dissemination
Ethics and safety consideration
This approval covers the protocol, informed consent
forms and the data collection forms. To date, no
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as well as sociodemographic and clinical data. Means and
SD will be reported for continuous variables and proportions will be calculated for categorical and nominal variables. Potentially relevant preprocedural and procedural
variables will be included in covariate model (analysis of
covariance) in an attempt to determine predictors of pain
scores reduction. All secondary analysis will be carried
out according to the intention-to-treat principle. For
superiority testing, a p value <0.05 will be considered as
indicating statistical significance.
Preplanned subgroups non-inferiority analyses will be
carried out for the primary outcomes based on age group
(4–7 years vs 8–12 years vs 13–17 years). As we will not
have the statistical power in each subgroup to conclude
to non-inferiority, the results will be considered as exploratory and will primarily serve for hypothesis generation
for future studies. Subgroups superiority analyses will be
also performed by age group for secondary outcomes.
Multiple imputation methods and sensitivity analysis will
be used when possible and appropriate to handle the
missing data.
No formal interim analysis is planned for this non-inferiority trial for different reasons. First, there is no necessity
to conduct interim analysis for futility reasons in non-inferiority trials considering that even if non-inferiority is
established before the completion of the trial, the data
collection should be pursued in hope of demonstrating
superiority.51 Second, considering that we do not expect
potentially serious adverse events, interim analysis for
safety reasons and stoppings rules are not required.50 71
There is also no need to implement a data monitoring
committee as the known risks are minimal for both interventions.50 72 73

Open access

Dissemination
The research protocol has been already presented to
local clinicians and stakeholders, as well as at national
and international conferences. Scientific results will be
disseminated at regional, national and international
conferences targeting nurses, emergency physicians and
paediatric researchers. A manuscript will be submitted to
a high impact peer-reviewed journal.
Trial status
Recruitment for this study is ongoing.
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